Latest / "Isn't That Interesting?!": Breast Cancer Survivor Stories + Remarkable Research / Episode 12: Dr. Savannah Partridge {University of Washington}
Transcript
- 0:00When it comes to detecting breast cancer, image means a
- 0:04lot. Specifically, a diffusion,
- 0:07weighted MRI, a mouthful for some of us.
- 0:10But for one Washington researcher, the picture is clear
- 0:13as an earlier detection method and more.
- 0:16Here's Martha Kaley, founder and executive directorofearlier.org
- 0:20with this edition of Isn't That Interesting?
- 0:24Well, I'd like to welcome everybody to this week's episode
- 0:27of Isn't That Interesting with Doctor Savannah Partridge, who
- 0:31is a Professor of Radiology in the Breast Imaging section at
- 0:35the University of Washington. A large focus of her work has
- 0:39been to investigate dynamic contrast enhanced MRI and
- 0:44diffusion weighted MRI for improved detection and diagnosis
- 0:49of breast cancer. And Doctor Partridge received a
- 0:52grant from earlier.org in 2016 for $40,000 for non contrast
- 0:59diffusion weighted MRI tailored by for earlier detection of
- 1:03mammographical occult breast cancer in women with dense
- 1:07breasts. Can you tell I had to read that.
- 1:09So it's a mouthful, Yes. But I'm just going to ask you to
- 1:15tell us a little bit about kind of describe what diffusion
- 1:19weighted imaging with MRI and help us understand in layman's
- 1:24terms that. OK, yes, thank you.
- 1:28Thank you for that nice introduction.
- 1:29It's. So such a pleasure to be.
- 1:31Able to. Come and talk.
- 1:32To you all today about some of the.
- 1:33Work. We've been doing that.
- 1:34Has been supported. By your efforts so.
- 1:37I think it's helpful to just kind of give a little context.
- 1:40Before we. Describe what that?
- 1:42Particular Mr. Technique is so. Just to back up my research,
- 1:48yes, I'm a research faculty in the radiology department.
- 1:51My background is in imaging physics and very.
- 1:54Early. I got interested in breast
- 1:57cancer in particular as an area that I wanted to try and, you
- 2:00know, improve outcomes for, and that led me to looking at
- 2:05advanced imaging techniques that could.
- 2:07Help us to better. Detect and diagnose breast
- 2:09cancer and. As part of that, I.
- 2:12Got interested in MRI and so MRI is not our standard imaging
- 2:16technique that we think of. We're typically more familiar
- 2:18with X-ray mammography, which. Is a.
- 2:21Widely used screening tool, but MRI has a lot of advantages over
- 2:25mammography. It's got the.
- 2:27Much. Higher sensitivity for.
- 2:28Detecting very small or. Early stage disease.
- 2:32It's more sensitive to those more aggressive breast cancer.
- 2:36Subtypes. So can pick.
- 2:37Those up earlier. And also.
- 2:40Can give us physiologic. Information about the tumor so
- 2:43we can help understand its biology a little more.
- 2:45So it gives us a lot of opportunities to learn more and
- 2:47detect earlier and learn more. So that, you know, made me
- 2:50interested very early on and so. Here.
- 2:54The reason why it? LED us to this.
- 2:56Diffusion weighted MRI technique The more the more common
- 2:59approach for breast MRI, if you've ever had one, is that you
- 3:01will get an injection of a contrast agent and so.
- 3:05That helps us see. Breast cancer very well on MRI
- 3:09we are. Exploiting the.
- 3:10Changes in the. Tumor vascularity.
- 3:13Or the blood vessels that. Happen and.
- 3:14So the contrast agent we inject. Leaks out.
- 3:17And we can see it on the MRI and it's.
- 3:19Very helpful for. Lighting up those, you know,
- 3:22small cancers. But that also creates a barrier.
- 3:25To providing this screening tool.
- 3:28To a lot. A wider.
- 3:30Group of women. Because because of the need.
- 3:32For the contrast agent, injection it.
- 3:34Adds to the. Expense and the time and the
- 3:37inconvenience and potential. Toxicities of this.
- 3:39Screening exam so our feeling about trying to.
- 3:43Address this need for earlier. Breast cancer detection was to
- 3:46try and improve upon the breast MRI technique.
- 3:48So that we. Could.
- 3:49Offer it more widely to more women who could use it.
- 3:52Right now it's not used as widely as as would be nice and
- 3:56a. Lot of that.
- 3:57Has to. Do with the expense and the need
- 3:59for this contrast agent injection and so if we.
- 4:02Could get rid. Of the need to inject the
- 4:04contrast agent, we felt this would be something that could be
- 4:07a much, you know, more cost. Effective.
- 4:09Faster. Exam and it just would be a more
- 4:12convenient exam and and people who are not able to get the
- 4:16contrast agent or do not want to get the contrast agent wouldn't
- 4:18be avoiding it basically. So.
- 4:21So that led us to. Diffusion weighted MRI and this
- 4:25is a a different type of MRI scan that we can do.
- 4:29It doesn't require an injection of a contrast agent.
- 4:31What? It really does.
- 4:32Is measure the motion of water molecules that are naturally
- 4:36moving in your tissue just due to thermal energy?
- 4:39Because we can measure. That.
- 4:40Water motion. We can indirectly measure the
- 4:43microstructure. Of the tissue.
- 4:44Because anything that is impacting the motion of the
- 4:46water. You know, barriers.
- 4:48That if they're encountering, we can we can measure C.
- 4:53Because of. This and.
- 4:54So. Things.
- 4:55Like higher cell? Density.
- 4:57Which is a. Characteristic of breast.
- 4:58Tumors can show up differently on the diffusion MRI versus the
- 5:02normal tissue and that's one one.
- 5:05Major factor that. I think helps.
- 5:06Us to be. Able to detect.
- 5:07Breast cancer on diffusion MRI, Yeah.
- 5:10So early on we got interested in whether or not this diffusion
- 5:14MRI could be useful for helping us see breast cancer without the
- 5:18need to inject the contrast agent.
- 5:19And that led. Us to apply for.
- 5:21The grant. To earlier to see if we could
- 5:24get a little pilot. Seed funding to.
- 5:27Kick off. You know, some research and
- 5:29collecting some preliminary data in this direction.
- 5:32Well, you know, that's so interesting for me to hear about
- 5:37the importance that that that earlier concept is and with, I
- 5:42don't know, $40,000 sounds like a lot, but in the research world
- 5:48is not a lot. I realize that.
- 5:50And that's kind of where we started.
- 5:53And this has been our goal with the organization is to fund
- 5:57those potential concepts to, to see if we can spring out of some
- 6:03of the locked it like we're locked into looking at it from
- 6:06certain ways. And I love the fact that with
- 6:09this, with this research, we would be eliminating the
- 6:14contrast agent. I know that that has been a
- 6:16concern for a number of years and it's still I think a, a
- 6:21major concern. So how great would that be to
- 6:23branch out away from that? So with the grant from earlier
- 6:29in your information and it was like it was kind of running
- 6:31parallel to one of the the major study with diffusion weighted.
- 6:36So how did that help with getting that that information
- 6:40out? Yeah.
- 6:42So we've been interested in diffusion MRI, not just for.
- 6:44This application the. Screening application but.
- 6:47We've realized that. Earlier on we were interested in
- 6:50it. Because it was.
- 6:51We knew it could tell us more. About the biology.
- 6:54Or the microstructure of tissue. And could actually be used in a
- 6:57complementary fashion to the usual exam.
- 7:00So not trying to get rid of the contrast agent, but to add extra
- 7:03information that radiologist and clinicians could.
- 7:06Use to improve. Their diagnosis?
- 7:09Particularly to help. Them reduce the number of.
- 7:11False positives. That we were getting from breast
- 7:13MRI, that's another big. Barrier.
- 7:15Criticism of breast MRI. It's highly sensitive.
- 7:17But it also. Picks up things that are not
- 7:20cancer and that can lead to unnecessary.
- 7:22Biopsies so. Early on we were doing work in
- 7:25diffusion MRI to. See if.
- 7:27We could use. That information to help.
- 7:29Them decide. Whether or not something was
- 7:30suspicious enough to warrant a biopsy and so.
- 7:34Because of that, we had started that work earlier before this.
- 7:37Earlier. Grant and.
- 7:40That led us. To you know.
- 7:42Kind of a similar fashion. We got pilot funding early.
- 7:46On to really. Test that approach that led.
- 7:49To an NIH grant and then that led to actually a large multi
- 7:52center. Trial that we were.
- 7:53Able to run which showed you know.
- 7:55Validated that this could be a viable.
- 7:57Approach to reduce. Unnecessary biopsies.
- 8:00The. You know, along the way.
- 8:03That is how. We noticed that.
- 8:04We could, actually. See.
- 8:05Some of these cancers on the diffusion.
- 8:08Without. You know, even looking at the
- 8:11contrast enhanced exam and that was what spawned us to, you
- 8:15know, prompted us to. Apply to the earlier.
- 8:17Organization to see if we could get some early funding to look
- 8:20at it. For this.
- 8:20Reason, and you know the reason we needed the seed funding from.
- 8:25Earlier was. To be able to tailor the.
- 8:28Exam More. For that purpose because it.
- 8:31Hadn't been yet so we could maximize.
- 8:33The visibility of. The cancer on the exam, we felt
- 8:37if we put a little more attention on that and put some
- 8:39time into it and. Studied.
- 8:41It a little further just for that.
- 8:43And so the. Earlier seed.
- 8:44Grant gave us the, you know, it was a good amount of money, not
- 8:48a lot of amount of money like you're saying in the in.
- 8:51The larger scope. Of things, of what we need to to
- 8:53do to actually translate something from, you know, bench
- 8:55to bedside. But it allowed us to.
- 8:58Fine tune or optimize the sequence.
- 9:00For the purpose. Of screening and then to test it
- 9:03out in some patients that. You know we could.
- 9:06See how would. Perform so it gave us the money
- 9:09to you know pay for some additional MRI scans and things
- 9:12like that it. Was pretty critical.
- 9:14For helping us to. Really test out our.
- 9:16Hypothesis and get us. The.
- 9:18Preliminary funding we needed and then I wanted to mention
- 9:21that after that. Earlier.org.
- 9:23Project the. One we're talking about today,
- 9:25the screening non contrast MRI we.
- 9:28Were able to use the data. That we got from this this.
- 9:32Study. And put it into a NIHRO 1 grant
- 9:36and we were able. To successfully.
- 9:38Obtain A5 year RO 1 grant to. Study this further so.
- 9:42This is something we've been working on for a while and it
- 9:44all kind of started, I would say, from the.
- 9:46Earlier.org. Pilot funding that we got well
- 9:49that is so great and did I read somewhere that that you this
- 9:53could serve as a purpose for following the like treatment
- 9:57therapy if right, that's another.
- 10:00That's that's another. Application of diffusion MRI.
- 10:02We're exploring as well this. Particular technique has really.
- 10:07Taken off, I would say in the field just.
- 10:09For all the. Different ways that we could.
- 10:11Potentially be using it. For the screening non contrast
- 10:14approach for reducing unnecessary.
- 10:16Biopsies associated. With the conventional exam, but
- 10:19then also for monitoring response to.
- 10:21Therapy because. You know the.
- 10:24Technique is very sensitive to that.
- 10:26Tissue microstructure and cellular density and tumor
- 10:29microenvironment. What we found is that, you know,
- 10:32as women are undergoing chemotherapy.
- 10:35This is. Particularly for.
- 10:36Women that are getting. Therapy before surgeries.
- 10:39What we call neoadjuvant or preoperative chemotherapy, we
- 10:42can we can see changes in the tumor on the diffusion MRI that
- 10:46occur before any changes in size are apparent and we.
- 10:50Also had another large. Trial that we.
- 10:52Ran to look at that. To look at.
- 10:54Whether this diffusion? MRI could be used as a
- 10:56biomarker. To help guide.
- 10:58Treatment decisions and found that we could.
- 11:02Indeed, predict accurately. The outcome?
- 11:05Of the therapy. About midway into treatment
- 11:07using this diffusion MRI. So it's very exciting as a new
- 11:11biomarker that we're hoping to. Be able to.
- 11:14You know, move into clinical. Practice so that.
- 11:17You know. Doctors have this.
- 11:18Tool at their disposal. For helping tailor.
- 11:20Therapies. For better outcomes.
- 11:22So how soon do you think that that can be moved into a
- 11:25clinical scene? So.
- 11:27I think it depends on which application we're talking about.
- 11:30I think the application the treatment response application
- 11:33is is further along. I would.
- 11:35Say we've already. Gotten to the point of having
- 11:37run a multi. Centre Study.
- 11:39A national multi centre study that we ran that was NCI funded,
- 11:43that use as a biomarker has you know been.
- 11:47Incorporated into larger. Clinical.
- 11:49Trials already so. People are recognizing its
- 11:51value. We did identify that there's
- 11:54some challenges that need to be addressed when using.
- 11:57Always right? So when we have a new
- 11:59technology, you know the multi center trials.
- 12:02I would say. Are you know something critical
- 12:03that we need to do before we can translate into clinical routine?
- 12:08Because it really. Helps us understand how.
- 12:10Well, these. Tools are.
- 12:11Performing outside of a single institution, right?
- 12:14So if I get funding from earlier and run a small study.
- 12:17I get some very promising. Results.
- 12:20We still need to. Show that if we try and do.
- 12:22This beyond our own institution, on our own scanner equipment
- 12:25that it's going to work otherwise it's not that.
- 12:28Useful. To the world, to the to the
- 12:30wider. Population so.
- 12:32We've already gone past that with the.
- 12:34Treatment response application and there we found that you know
- 12:37it. It.
- 12:38It was a. A good biomarker that can
- 12:41predict outcomes to treatment. But there are.
- 12:44Image. Quality variabilities that.
- 12:46Can occur across. Different scanners and a.
- 12:48Different site so we. Learned that we need to really
- 12:50standardize the technique and really, you know, pay close
- 12:54attention to making sure that everyone's doing it in a similar
- 12:57way and then we're all following the same.
- 13:00Approach to both the. Acquisitions and the
- 13:02interpretations when we're actually looking at this images
- 13:06and taking measurements from the images, we all need to you know.
- 13:09Follow a recipe of how to do that so.
- 13:11That we get, you know, similar. Performance when we're trying to
- 13:13use it as a biomarker, well, I think it's really exciting.
- 13:17I think this, it just has such potential.
- 13:21And, you know, one of the things I'd like to address is
- 13:24sometimes, well, as a patient, I can say, you know, if there's
- 13:29something that the radiologist sees on a, on a mammogram and
- 13:33they go, well, maybe we just need to look at this.
- 13:37Maybe we need to do an MRI. Let's, you know, let's look at
- 13:40that. I would like to alleviate some
- 13:43of the fear factor for moving forward and to, to help all of
- 13:49us just realize that this is just another step and, and being
- 13:53more definitive. And I think that that is a
- 13:55wonderful opportunity for us to embrace that concept of this is
- 14:02just one more step in assessing. Yeah.
- 14:05I know that's very true and. So a lot of the work.
- 14:07That, you know, myself and others are working on is
- 14:10improving that MRI scan as a, as a diagnostic and detection tool
- 14:14and getting rid of, you know these.
- 14:17Additional false positives. That we're.
- 14:19Having that can help, you know, the patient experience quite a
- 14:22bit and bring down anxiety and costs.
- 14:25We hope, you know, if it's just more straightforward, if we can
- 14:28eliminate the need for the contrast agent, that's going to
- 14:30reduce the time involved and you know, the need to, you know,
- 14:35have an IV injection during the exam.
- 14:37And, and so I think it can just get to a point where it's a much
- 14:41quicker, simpler exam. Nothing to be.
- 14:43Worried about, like you said, just.
- 14:45Another, you know, step that gives us more information about,
- 14:48about what's going on in the breast, right.
- 14:51And I, I think it's very exciting to know that you could
- 14:55be observing whether therapy is working because that seems to
- 15:00have such an impact about the timing on that with four, the
- 15:06field is really moving in such a, you know, more personalized
- 15:09treatment direction and there. Are lots.
- 15:12Of examples where treatment schemas are designed.
- 15:16So that there. Are points along the treatment
- 15:19pathway you know? Look where we.
- 15:22Monitor the response and if the patient is.
- 15:25Observe to have had a very. Good response.
- 15:27They may be able to consider foregoing any you know.
- 15:30Further toxic chemotherapy. And being able to avoid, you
- 15:34know, skip that because they don't need it and they're not
- 15:36getting any further benefit from it, right.
- 15:39And, and we really haven't had that tool to use.
- 15:42Well, I think unless you have any more that you'd like to say
- 15:45I one other question that I do have for you is about AI and AI
- 15:51with it. So can you just jump in a little
- 15:53bit on that? Yeah.
- 15:55I mean, I think when we're thinking about what are our next
- 15:57steps here of where we want to go from, you know?
- 16:00As I. Described we had the earlier
- 16:02project that allowed. Us to collect some.
- 16:04Very critical. Preliminary data and showed
- 16:07proof of concept, then we were able to spin that up into an NIH
- 16:11five year grant, which we're wrapping up and kind of
- 16:14finalizing the analysis, the next steps.
- 16:17As we look forward are to. Number one, see how AI can help.
- 16:21Here. Because we really.
- 16:22Hadn't had time to do that yet, we know.
- 16:25We're very excited about the prospects.
- 16:26Of being able to incorporate. AI both.
- 16:29For improving the. Image, Image quality has been a
- 16:34challenge for diffusion MRI didn't really get to go into it,
- 16:37but it's a much more technically challenging type of MRI scan
- 16:41compared to the standard ones. And so because of that, we tend
- 16:45to have. A bit lower spatial.
- 16:46Resolution and some other factors.
- 16:48But with AI, we're starting to be able to recover that.
- 16:52Spatial resolution through. AI approaches, which is.
- 16:55Pretty amazing and that can help us, you know again.
- 16:58Detect earlier disease. And, you know, be most
- 17:01sensitive. There.
- 17:04And so also being able to incorporate all of the
- 17:06information from other types of non contrast Mr. scan.
- 17:09So not just the diffusion, but there are other.
- 17:11Types of. Images.
- 17:13That we can obtain with MRI that don't have contrast and can all.
- 17:17Add to the. The bigger picture and and the.
- 17:20Ability to detect. That cancer earlier.
- 17:22So I think, I think the performance will go up even
- 17:24more, you know, being able to. Leverage AI for for this
- 17:28purpose. Yeah, well, I'm ready for it to
- 17:30happen, all right. No, I know.
- 17:32Yeah. So that that's.
- 17:34Where our next? Grants are focusing is, you
- 17:36know, incorporating AI and trying to.
- 17:38Boost. Performance even more, but then
- 17:41also moving this forward into a multi center.
- 17:43Trial itself is. Something that we're we're
- 17:45focused on right now as well. We think it's, you know, ready.
- 17:49We just need to, you know, get a little more preliminary data
- 17:52that, you know, shows that it's going to be.
- 17:54Feasible across. Systems and across centers and
- 17:57then really see how it performs so we can offer.
- 17:59This as a. Alternate tool.
- 18:01In the field for. For breast screening, well, I
- 18:05really appreciate your work. I just value it so much and I
- 18:10think it's such a positive think it's such positive information
- 18:14for anybody that's listening to understand that how we are
- 18:18progressing with it. So thank you so much for being
- 18:22willing to chat with us and we wish you the very best on all of
- 18:26your projects. Oh, thank you so much.
- 18:28It's been a pleasure and thank you to you and all your
- 18:30contributors for helping really kick off and support our.
- 18:33Research. We couldn't have done it without
- 18:35you. Thank you.
- 18:36Thank you. This episode of Isn't That
- 18:40Interesting was made possible thanks to volunteers and donors
- 18:43just like you. It was hosted by Martha Kaley,
- 18:46founderofearlier.org and edited by Liam Mcburney.
- 18:50I'm Valerie Amsterdam, reminding you that for the last 30 years,
- 18:54this is North Carolina based organization has helped fund
- 18:57groundbreaking research all over the world from molecular imaging
- 19:02to a sensitive blood test for breast cancer.
- 19:05Plain and simple, earlier detection saves lives.
- 19:07And you can help host a fundraising event, make a
- 19:10donation for volunteer your time.
- 19:13You can find us not only on the web, but on Facebook and
- 19:15Instagram too. Let's change the picture of
- 19:18breast cancer together.